Please use this identifier to cite or link to this item: http://hdl.handle.net/10609/147713
Title: Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging
Author: Cortese, Rosa  
Prados Carrasco, Ferran  
TUR, CARMEN  
Bianchi, Alessia  
Brownlee, Wallace
De Angelis, Floriana  
Paz, Isabel de la
Grussu, Francesco  
Haider, Lukas  
Jacob, Anu
Kanber, Baris  
Magnollay, Lise
Nicholas, Richard
Trip, Anand
Yiannakas, Marios  
Toosy, Ahmed  
Hacohen, Yael  
Barkhof, Frederik  
Ciccarelli, Olga  
Others: University College London (UCL)
University of Siena
Universitat Oberta de Catalunya. eHealth Center
Vall d'Hebron Institute of Research
Medical University of Vienna
NMOClinical Service Walton Centre
Imperial College London
University College London Hospitals
Citation: Cortese, R., Prados, F., Tur, C., Bianchi, A., Brownlee, W.J., De Angelis, F., De la Paz, I., Grussu, F., Haider, L., Jacob, A., Kanber, B., Magnollay, L., Nicholas, R., Trip, A., Yiannakas, M.C., Toosy, A.T., Hacohen, Y., Barkhof, F. & Ciccarelli, O. (2023). Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging. Neurology, 100(3), E308-E323. doi: 10.1212/WNL.0000000000201465
Abstract: Background and Objectives Relapsing-remitting multiple sclerosis (RRMS), aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) may have overlapping clinical features. There is an unmet need for imaging markers that differentiate between them when serologic testing is unavailable or ambiguous. We assessed whether imaging characteristics typical of MS discriminate RRMS from AQP4-NMOSD and MOGAD, alone and in combination. Methods Adult, nonacute patients with RRMS, APQ4-NMOSD, and MOGAD and healthy controls were prospectively recruited at the National Hospital for Neurology and Neurosurgery (London, United Kingdom) and the Walton Centre (Liverpool, United Kingdom) between 2014 and 2019. They underwent conventional and advanced brain, cord, and optic nerve MRI and optical coherence tomography (OCT). Results A total of 91 consecutive patients (31 RRMS, 30 APQ4-NMOSD, and 30 MOGAD) and 34 healthy controls were recruited. The most accurate measures differentiating RRMS from AQP4-NMOSDweretheproportion of lesions with the central vein sign (CVS) (84% vs 33%, accuracy/specificity/sensitivity: 91/88/93%, p < 0.001), followed by cortical lesions (median: 2 [range: 1–14] vs 1 [0–1], accuracy/specificity/sensitivity: 84/90/77%, p = 0.002) and white matter lesions (mean: 39.07 [±25.8] vs 9.5 [±14], accuracy/specificity/sensitivity: 78/84/73%, p = 0.001). The combination of higher proportion of CVS, cortical lesions, and optic nerve magnetization transfer ratio reached the highest accuracy in distinguishing RRMS from AQP4-NMOSD (accuracy/specificity/sensitivity: 95/92/97%, p < 0.001). The most accurate measures favoring RRMSoverMOGADwerewhitematterlesions(39.07[±25.8]vs 1 [±2.3], accuracy/specificity/sensitivity: 94/94/93%, p = 0.006), followed by cortical lesions (2 [1–14] vs 1 [0–1], accuracy/specificity/sensitivity: 84/97/71%, p = 0.004), and retinal nerve fiber layer thickness (RNFL) (mean: 87.54 [±13.83] vs 75.54 [±20.33], accuracy/specificity/sensitivity: 80/79/81%, p = 0.009). Higher cortical lesion number Glossary 9-HPT = 9-hole peg test; Ab = antibody; AQP4-NMOSD = aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder; AUC = area under the curve; CBA = cell-based assay; CSA = cross-sectional area; CVS = central vein sign; DTI = diffusion tensor imaging; EDSS = Expanded Disability Status Scale; GCIPL = ganglion cell–inner plexiform layer; MOGAD = myelin oligodendrocyte glycoprotein antibody–associated disease; MTR = magnetization transfer ratio; OCT = optical coherence tomography; RC = regression coefficient; RRMS = relapsing-remitting multiple sclerosis; SWI = susceptibilityweighted imaging; TWT = timed 25-foot walk test.
Keywords: all demyelinating disease (CNS)
multiple sclerosis
class II
devic's syndrome
MRI
DOI: https://doi.org/10.1212/wnl.0000000000201465
Document type: info:eu-repo/semantics/article
Version: info:eu-repo/semantics/publishedVersion
Issue Date: 17-Jan-2023
Publication license: https://creativecommons.org/licenses/by/4.0/  
Appears in Collections:Articles
Articles cientÍfics

Share:
Export:
View statistics

Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.